Page 91 - 《中国药房》2025年11期
P. 91
Evidence from a retrospective analysis in a cohort of cer[J]. Value Health,2011,14(6):836-845.
Chinese patients[J]. Front Endocrinol (Lausanne),2022, [17] RUI M J,FEI Z Y,WANG Y C,et al. Cost-effectiveness
13:947443. analysis of sintilimab + chemotherapy versus camreli‐
[ 4 ] SOCINSKI M A,OBASAJU C,GANDARA D,et al. Cur‐ zumab + chemotherapy for the treatment of first-line lo‐
rent and emergent therapy options for advanced squamous cally advanced or metastatic nonsquamous NSCLC in
cell lung cancer[J]. J Thorac Oncol,2018,13(2):165-183. China[J]. J Med Econ,2022,25(1):618-629.
[ 5 ] LAU S C M,PAN Y W,VELCHETI V,et al. Squamous [18] SHAO T H,REN Y N,ZHAO M Y,et al. Cost-
cell lung cancer:current landscape and future therapeutic effectiveness analysis of camrelizumab plus chemo‐
options[J]. Cancer Cell,2022,40(11):1279-1293. therapy as first-line treatment for advanced squamous
[ 6 ] 国家卫生健康委办公厅 . 关于印发原发性肺癌等 18 个 NSCLC in China[J]. Front Public Health,2022,10:
肿瘤诊疗规范(2018年版)的通知[EB/OL].(2018-12-13) 912-921.
[2024-11-10]. http://www.nhc.gov.cn/yzygj/s7659/201812/ [19] 刘国强,康朔,王欣晨.帕博利珠单抗一线治疗PD-L1高
b21802b199814ab7b1219b87de0cae51.shtml. 表达的晚期非小细胞肺癌的药物经济学评价[J].中国药
[ 7 ] LI X L,SHAO C S,SHI Y F,et al. Lessons learned from 房,2021,32(11):1351-1356.
the blockade of immune checkpoints in cancer immuno‐ [20] 齐冉,聂旭阳,刘旭婷,等. 斯鲁利单抗联合化疗方案一
therapy[J]. J Hematol Oncol,2018,11(1):31. 线治疗广泛期小细胞肺癌的药物经济学评价[J]. 中国药
[ 8 ] DHILLON S. Penpulimab:first approval[J]. Drugs,2021, 房,2023,34(11):1368-1373.
81(18):2159-2166. [21] NAFEES B,LLOYD A J,DEWILDE S,et al. Health state
[ 9 ] ZHONG H,SUN S J,CHEN J H,et al. First-line penpu‐ utilities in non-small cell lung cancer:an international
limab combined with paclitaxel and carboplatin for meta‐ study[J]. Asia Pac J Clin Oncol,2017,13(5):e195-e203.
static squamous non-small-cell lung cancer in China [22] ALLEMANI C,WEIR H K,CARREIRA H,et al. Global
(AK105-302):a multicentre,randomised,double-blind, surveillance of cancer survival 1995-2009:analysis of in‐
placebo-controlled phase 3 clinical trial[J]. Lancet Respir dividual data for 25 676 887 patients from 279 population-
Med,2024,12(5):355-365. based registries in 67 countries (CONCORD-2)[J]. Lan‐
[10] HAN B,CHEN J,WANG Z,et al. Penpulimab in combi‐ cet,2015,385(9972):977-1010.
nation with anlotinib as first-line treatment in advanced [23] ALLEMANI C,MATSUDA T,DI CARLO V,et al.
nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, Global surveillance of trends in cancer survival 2000-14
2021,39 (15):e21072-e21072. (CONCORD-3):analysis of individual records for
[11] 中国医师协会肿瘤医师分会,中国医疗保健国际交流促 37 513 025 patients diagnosed with one of 18 cancers
进会肿瘤内科分会 .Ⅳ期原发性肺癌中国治疗指南: from 322 population-based registries in 71 countries[J].
2023年版[J].中国综合临床,2023,39(3):161-190. Lancet,2018,391(10125):1023-1075.
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 [24] CARLISLE J W,STEUER C E,OWONIKOKO T K,
(CSCO)免疫检查点抑制剂临床应用指南:2024[M]. 北 et al. An update on the immune landscape in lung and
京:人民卫生出版社,2024:54. head and neck cancers[J]. CA Cancer J Clin,2020,70(6):
[13] 中华医学会肿瘤学分会,中华医学会杂志社 . 中华医学 505-517.
会肺癌临床诊疗指南:2023 版[J]. 中华肿瘤杂志,2023, [25] XU L Z,CHEN M S,ANGELL B,et al. Establishing cost-
45(7):539-574. effectiveness threshold in China:a community survey of
[14] 刘国恩. 中国药物经济学评价指南2020[M]. 北京:中国 willingness to pay for a healthy life year[J]. BMJ Glob
市场出版社,2020:27-115. Health,2024,9(1):e013070.
[15] 刘家一,李伟 . R 语言实例解析肿瘤治疗药物经济学评 [26] ZHAO Z X,YANG Y,WU W J,et al. Willingness to pay
价的分区生存模型[J]. 数理医药学杂志,2024,37(4): for cancer prevention versus treatment in China:implica‐
240-251. tions for cost-effectiveness threshold[J]. Expert Rev Phar‐
[16] GOULART B,RAMSEY S. A trial-based assessment of macoecon Outcomes Res,2024,24(1):155-160.
the cost-utility of bevacizumab and chemotherapy versus (收稿日期:2024-12-06 修回日期:2025-05-12)
chemotherapy alone for advanced non-small cell lung can‐ (编辑:孙 冰)
中国药房 2025年第36卷第11期 China Pharmacy 2025 Vol. 36 No. 11 · 1369 ·